• (Z)-4-Hydroxytamoxifen in ER Research

  2026-08-26

  Use (Z)-4-Hydroxytamoxifen to resolve estrogen receptor biology with greater pharmacological precision than the parent compound. This guide connects ER assays with proliferation-tracing relapse models, providing practical formulation, workflow, control, and troubleshooting strategies for preclinical breast cancer research.

• TMRE Mitochondrial Membrane Potential Assay Kit

  2026-08-25

  Learn how TMRE mitochondrial membrane potential assay kit SKU K2233 supports reproducible mitochondrial depolarization measurement in cell viability, apoptosis, and metabolic-stress studies. This scenario-based guide covers assay principles, controls, workflow optimization, interpretation, and practical vendor-selection criteria.

• Mecamylamine Hydrochloride in Gut-Brain Assays

  2026-08-25

  Mecamylamine hydrochloride offers a pharmacological way to interrogate nicotinic receptor dependence in gut-brain research. This article explains how to integrate mecamylamine into causal assay designs inspired by new Bacteroides fragilis epilepsy findings while preserving appropriate controls and mechanistic restraint.

• Modeling Breast Cancer Relapse with PyMT ProTracer

  2026-08-24

  The reference study introduces a dual-recombinase system that traces and ablates recently proliferating cells in spontaneous MMTV-PyMT mammary tumors. Relapse after ablation was associated with residual low-cycling tumor cells, cancer stem-like populations, protumor γδ T cells, and coordinated Spp1–Vegfa expression in myeloid cells, creating a practical model for studying recurrent disease.

• Asunaprevir (BMS-650032) HCV Research Guide

  2026-08-24

  Asunaprevir (BMS-650032) combines nanomolar NS3/4A protease inhibition with broad genotype-oriented utility, making it useful for biochemical, replicon, and translational HCV workflows. This guide explains how to build a reliable assay cascade, separate direct antiviral activity from cytotoxicity, and apply the screening logic of a landmark chemical-biology study without confusing antiviral and chromatin mechanisms.

• Bortezomib Assay Design: Measure Death, Not Just Viability

  2026-08-23

  Bortezomib (PS-341) can reveal proteasome-dependent stress, but viability alone may obscure whether cells stop dividing or die. This guide translates key findings from a cancer pharmacology dissertation into practical, multiparameter assay decisions.

• Acetylspiramycin: Resistance Assay Workflows

  2026-08-22

  Acetylspiramycin (Spiramycin B) combines 50S ribosomal targeting with practical value in macrolide-resistance and host–pathogen studies. This guide translates its solubility, component-control, and susceptibility-testing considerations into executable bench workflows.

• Hyperthermia–Cisplatin Activates Caspase-8

  2026-08-21

  The reference study identifies caspase-8 accumulation and activation as a mechanistic link between hyperthermia and cisplatin-enhanced apoptosis and pyroptosis in cancer cells. Its combination of ubiquitination analysis, genetic perturbation, biochemical assays, and ultrastructural imaging provides a framework for interpreting caspase-8-dependent cell death rather than treating caspase activation as a single endpoint.

• Sodium-Driven Mitochondrial Failure in NECSO

  2026-08-20

  Qiao and colleagues identify mitochondrial energy failure as the mechanistic link between TRPM4-mediated sodium influx and necrosis by sodium overload (NECSO). Their work connects mitochondrial sodium accumulation, NCLX-dependent calcium loss, impaired oxidative metabolism, ATP depletion, and Na/K-ATPase failure into a causal pathway relevant to disorders involving pathological sodium loading.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-08-20

  Shiota and colleagues developed a dCas9-based reporter screen to identify compounds that suppress NUT-dependent transcription, revealing structurally diverse HDAC inhibitors as potent repressors of the BRD4-NUT oncogenic program. Panobinostat and IRBM6 reduced megadomain-associated oncogene expression, promoted differentiation, and restrained tumor growth in preclinical models, providing a mechanistic rationale for targeting chromatin acetylation in NUT carcinoma.

• CCK-8–NOX4 Signaling Drives ANP Secretion

  2026-08-19

  The reference study identifies a mechanistic pathway in which sulfated cholecystokinin octapeptide activates CCK receptors, increases AA-dependent NOX4 and H2O2 signaling, and promotes ANP secretion through PGC-1α–PPARα/PPARγ activation in isolated beating rat atria. Its ex vivo design links atrial contractile changes with endocrine output and provides a useful framework for studying redox-regulated cardiac signaling.

• Bsa I (RNase-free): Protocol and QC Guide

  2026-08-19

  Bsa I (RNase-free), SKU K1095, provides sequence-specific type IIS DNA cleavage for cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination must be minimized. It is intended for scientific research only, not diagnostic or medical use, and operating conditions should be confirmed against the current product instructions rather than inferred from unrelated enzyme formulations.

• Apicidin and Oocyte Quality: Meiotic and Epigenetic Injury

  2026-08-18

  The 2026 reference study shows that Apicidin exposure impairs oocyte meiotic maturation by disrupting spindle assembly, chromosome alignment, actin organization, and histone acetylation. Its integrated cellular and molecular endpoints provide a framework for studying reproductive toxicity while clarifying why findings from oncology models should not be transferred directly to germ-cell biology.

• p-Cresyl Sulfate: CKD Assay Workflows

  2026-08-18

  Build reproducible cell and animal models of uremic cardiovascular injury with p-Cresyl sulfate, from fresh-solution handling to calcification, endothelial repair, and renal-clearance readouts. The workflow connects a biomarker for uremia-related cardiovascular risk with mechanistic assays centered on klotho/SIRT1, HIF-1α, NF-κB, and RUNX2.

• Kidney-Targeted mRNA Nanoparticles: Excipient Loading

  2026-08-17

  This 2024 Pace University dissertation examines whether excipients can address saturation in the mRNA loading capacity of polymeric mesoscale nanoparticles intended for kidney delivery. Its contribution is a comparative formulation and testing framework that connects encapsulation efficiency with particle size, cytotoxicity, uptake, pharmacokinetics, and protein expression.

541 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page